Adaptimmune Therapeutics PLC (ADAP)
1.025
0.00 (0.00%)
USD |
NASDAQ |
Jun 10, 14:48
Adaptimmune Therapeutics Cash from Investing (Quarterly): -0.358M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.358M |
December 31, 2023 | 68.20M |
September 30, 2023 | 57.31M |
June 30, 2023 | 2.694M |
March 31, 2023 | 48.34M |
December 31, 2022 | 20.95M |
September 30, 2022 | 28.85M |
June 30, 2022 | 44.11M |
March 31, 2022 | -4.775M |
December 31, 2021 | -28.49M |
September 30, 2021 | 34.85M |
June 30, 2021 | 47.68M |
March 31, 2021 | 21.76M |
December 31, 2020 | 7.608M |
September 30, 2020 | -27.58M |
June 30, 2020 | -187.00M |
March 31, 2020 | -71.95M |
December 31, 2019 | 23.68M |
Date | Value |
---|---|
September 30, 2019 | 35.04M |
June 30, 2019 | 18.56M |
March 31, 2019 | 17.66M |
December 31, 2018 | -52.41M |
September 30, 2018 | 0.942M |
June 30, 2018 | 20.37M |
March 31, 2018 | 13.64M |
December 31, 2017 | -40.01M |
September 30, 2017 | 9.751M |
June 30, 2017 | -73.18M |
March 31, 2017 | -22.64M |
December 31, 2016 | 16.96M |
September 30, 2016 | 5.743M |
June 30, 2016 | 5.617M |
March 31, 2016 | -10.56M |
September 30, 2015 | -9.862M |
December 31, 2014 | -26.18M |
September 30, 2014 | -0.5278M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-187.00M
Minimum
Jun 2020
68.20M
Maximum
Dec 2023
6.974M
Average
21.36M
Median
Cash from Investing (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | -- |
NuCana PLC | 0.0545M |
Autolus Therapeutics PLC | -0.533M |
TC BioPharm (Holdings) PLC | -0.0071M |
Mereo BioPharma Group PLC | -0.70M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -31.95M |
Cash from Financing (Quarterly) | 29.24M |
Free Cash Flow | -138.26M |
Free Cash Flow Per Share (Quarterly) | -0.1336 |
Free Cash Flow to Equity (Quarterly) | -32.31M |
Free Cash Flow to Firm (Quarterly) | -32.31M |
Free Cash Flow Yield | -61.29% |